Gina Mauro

Vice President of Content, OncLive and Cancer Network
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Articles

Elacestrant Significantly Improves PFS in Advanced ER+ Breast Cancer, Including ESR1-Mutant Subtype

December 7th 2021

The selective estrogen receptor degrader elacestrant (RAD1901) led to a 30% reduction in the risk of disease progression or death compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibition.

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia

November 30th 2021

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

FDA Schedules ODAC Meeting for Ublituximab/Umbralisib Combo in CLL/SLL

November 30th 2021

The FDA has scheduled a meeting of the Oncologic Drugs Advisory Committee (ODAC) to review the pending biologics license application/supplemental new drug application for the combination of ublituximab and umbralisib (Ukoniq; U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.

FDA Approves Pafolacianine Sodium Injection for Ovarian Cancer Identification

November 29th 2021

The FDA has approved pafolacianine sodium injection (Cytalux) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

Pembrolizumab/Lenvatinib Approved in Europe for Frontline RCC

November 29th 2021

The European Commission has approved the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced renal cell carcinoma.

European Commission Approves Pembrolizumab/Lenvatinib for Advanced or Recurrent Endometrial Cancer

November 29th 2021

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

Surufatinib Shows Comparable HRQoL Vs Placebo in Advanced Neuroendocrine Tumors

November 16th 2021

Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.

Liso-Cel/Ibrutinib Combo Improves Efficacy in Relapsed/Refractory CLL

November 16th 2021

Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.

Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC

November 15th 2021

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

Lanreotide Demonstrates Confirmed Efficacy in Advanced Bronchopulmonary NETs

November 11th 2021

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Checkpoint Blockade Moves Needle in Molecularly Driven Endometrial Cancer Paradigm

November 4th 2021

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

MRD Continues to Show Prognostic Potential in AML and Shape Treatment Decisions

November 3rd 2021

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

Risk-Stratification Can Be Used to Prevent Overtreatment in Children, AYA Patients With Synovial Sarcoma

October 25th 2021

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Fixed-Dose Eniluracil Under Investigation in Advanced Refractory Gastrointestinal Cancers

September 23rd 2021

Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.

Challenges Identified With Low Clinical Trial Accrual for AYA Patients With Sarcoma

September 23rd 2021

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

Adavosertib Improves PFS in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 21st 2021

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups

September 20th 2021

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

TG-1701 Monotherapy or Plus Ublituximab/Umbralisib Shows Encouraging Results in Relapsed/Refractory CLL

September 20th 2021

TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.